Martin Etzrodt
ETH Zurich
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Martin Etzrodt.
Science | 2009
Filip K. Swirski; Matthias Nahrendorf; Martin Etzrodt; Moritz Wildgruber; Virna Cortez-Retamozo; Peter Panizzi; Jose-Luiz Figueiredo; Rainer H. Kohler; Aleksey Chudnovskiy; Peter Waterman; Elena Aikawa; Thorsten R. Mempel; Peter Libby; Ralph Weissleder; Mikael J. Pittet
Monitoring Monocyte Reservoirs Monocytes are cells of the immune system that are recruited to sites of tissue injury and inflammation where they help to resolve the infection and are important for tissue repair. The bone marrow and blood are believed to be the primary reservoirs from which monocytes are mobilized after injury. Swirski et al. (p. 612; see the Perspective by Jia and Pamer) now demonstrate that the spleen also serves as a critical reservoir of monocytes that are recruited during ischemic myocardial injury. Monocytes in the spleen are very similar in phenotype to blood-derived monocytes and are mobilized to the injured heart, where they represent a large fraction of the total monocytes that are recruited. The chemoattractant, angiotensin II, is required for optimal monocyte mobilization from the spleen and emigration into injured tissue. A rapid deployment force of immune cells is identified in the spleen that is important for resolving inflammation. A current paradigm states that monocytes circulate freely and patrol blood vessels but differentiate irreversibly into dendritic cells (DCs) or macrophages upon tissue entry. Here we show that bona fide undifferentiated monocytes reside in the spleen and outnumber their equivalents in circulation. The reservoir monocytes assemble in clusters in the cords of the subcapsular red pulp and are distinct from macrophages and DCs. In response to ischemic myocardial injury, splenic monocytes increase their motility, exit the spleen en masse, accumulate in injured tissue, and participate in wound healing. These observations uncover a role for the spleen as a site for storage and rapid deployment of monocytes and identify splenic monocytes as a resource that the body exploits to regulate inflammation.
Nature | 2012
Partha Dutta; Gabriel Courties; Ying Wei; Florian Leuschner; Rostic Gorbatov; Clinton S. Robbins; Yoshiko Iwamoto; Brian Thompson; Alicia L. Carlson; Timo Heidt; Maulik D. Majmudar; Felix Lasitschka; Martin Etzrodt; Peter G. Waterman; Michael T. Waring; Adam T. Chicoine; Anja M. van der Laan; Hans W.M. Niessen; Jan J. Piek; Barry B. Rubin; Jagdish Butany; James R. Stone; Hugo A. Katus; Sabina A. Murphy; David A. Morrow; Marc S. Sabatine; Claudio Vinegoni; Michael A. Moskowitz; Mikael J. Pittet; Peter Libby
During progression of atherosclerosis, myeloid cells destabilize lipid-rich plaques in the arterial wall and cause their rupture, thus triggering myocardial infarction and stroke. Survivors of acute coronary syndromes have a high risk of recurrent events for unknown reasons. Here we show that the systemic response to ischaemic injury aggravates chronic atherosclerosis. After myocardial infarction or stroke, Apoe−/− mice developed larger atherosclerotic lesions with a more advanced morphology. This disease acceleration persisted over many weeks and was associated with markedly increased monocyte recruitment. Seeking the source of surplus monocytes in plaques, we found that myocardial infarction liberated haematopoietic stem and progenitor cells from bone marrow niches via sympathetic nervous system signalling. The progenitors then seeded the spleen, yielding a sustained boost in monocyte production. These observations provide new mechanistic insight into atherogenesis and provide a novel therapeutic opportunity to mitigate disease progression.
Proceedings of the National Academy of Sciences of the United States of America | 2012
Virna Cortez-Retamozo; Martin Etzrodt; Andita Newton; Philipp J. Rauch; Aleksey Chudnovskiy; Cedric R. Berger; Russell J.H. Ryan; Yoshiko Iwamoto; Brett Marinelli; Rostic Gorbatov; Reza Forghani; Tatiana Novobrantseva; Victor Koteliansky; Jose-Luiz Figueiredo; John W. Chen; Daniel G. Anderson; Matthias Nahrendorf; Filip K. Swirski; Ralph Weissleder; Mikael J. Pittet
Tumor-associated macrophages (TAMs) and tumor-associated neutrophils (TANs) can control cancer growth and exist in almost all solid neoplasms. The cells are known to descend from immature monocytic and granulocytic cells, respectively, which are produced in the bone marrow. However, the spleen is also a recently identified reservoir of monocytes, which can play a significant role in the inflammatory response that follows acute injury. Here, we evaluated the role of the splenic reservoir in a genetic mouse model of lung adenocarcinoma driven by activation of oncogenic Kras and inactivation of p53. We found that high numbers of TAM and TAN precursors physically relocated from the spleen to the tumor stroma, and that recruitment of tumor-promoting spleen-derived TAMs required signaling of the chemokine receptor CCR2. Also, removal of the spleen, either before or after tumor initiation, reduced TAM and TAN responses significantly and delayed tumor growth. The mechanism by which the spleen was able to maintain its reservoir capacity throughout tumor progression involved, in part, local accumulation in the splenic red pulp of typically rare extramedullary hematopoietic stem and progenitor cells, notably granulocyte and macrophage progenitors, which produced CD11b+ Ly-6Chi monocytic and CD11b+ Ly-6Ghi granulocytic cells locally. Splenic granulocyte and macrophage progenitors and their descendants were likewise identified in clinical specimens. The present study sheds light on the origins of TAMs and TANs, and positions the spleen as an important extramedullary site, which can continuously supply growing tumors with these cells.
Circulation | 2012
Clinton S. Robbins; Aleksey Chudnovskiy; Philipp J. Rauch; Jose-Luiz Figueiredo; Yoshiko Iwamoto; Rostic Gorbatov; Martin Etzrodt; Georg F. Weber; Takuya Ueno; Nico van Rooijen; Mary Jo Mulligan-Kehoe; Peter Libby; Matthias Nahrendorf; Mikael J. Pittet; Ralph Weissleder; Filip K. Swirski
Background— Atherosclerotic lesions are believed to grow via the recruitment of bone marrow–derived monocytes. Among the known murine monocyte subsets, Ly-6Chigh monocytes are inflammatory, accumulate in lesions preferentially, and differentiate. Here, we hypothesized that the bone marrow outsources the production of Ly-6Chigh monocytes during atherosclerosis. Methods and Results— Using murine models of atherosclerosis and fate-mapping approaches, we show that hematopoietic stem and progenitor cells progressively relocate from the bone marrow to the splenic red pulp, where they encounter granulocyte macrophage colony-stimulating factor and interleukin-3, clonally expand, and differentiate to Ly-6Chigh monocytes. Monocytes born in such extramedullary niches intravasate, circulate, and accumulate abundantly in atheromata. On lesional infiltration, Ly-6Chigh monocytes secrete inflammatory cytokines, reactive oxygen species, and proteases. Eventually, they ingest lipids and become foam cells. Conclusions— Our findings indicate that extramedullary sites supplement the hematopoietic function of the bone marrow by producing circulating inflammatory cells that infiltrate atherosclerotic lesions.
Science | 2012
Philipp J. Rauch; Aleksey Chudnovskiy; Clinton S. Robbins; Georg F. Weber; Martin Etzrodt; Ingo Hilgendorf; Elizabeth Tiglao; Jose-Luiz Figueiredo; Yoshiko Iwamoto; Igor Theurl; Rostic Gorbatov; Michael T. Waring; Adam T. Chicoine; Majd Mouded; Mikael J. Pittet; Matthias Nahrendorf; Ralph Weissleder; Filip K. Swirski
Immune Sentinels A classic paradigm in immunology holds that the immune response occurs in two waves: Rapidly responding cells of the innate immune system help to contain the invading pathogen and alert lymphocytes. These cells of the adaptive immune system then help to clear the infection and go on to form long-lasting memory. However, some specialized populations of lymphocytes can also respond quickly to an infection and carry out functions that overlap with the innate immune system. Now, Rauch et al. (p. 597, published online 12 January) describe one such cell type—innate response activator (IRA) B cells. IRA B cells recognize bacterial liposaccharide through Toll-like receptor 4 and, in response, produce the cytokine GM-CSF, which activates other innate immune cells. Deletion of IRA B cells in mice impaired their ability to clear a bacterial infection and promoted septic shock. A specialized population of B lymphocytes is important for controlling bacterial infections and preventing sepsis. Recognition and clearance of a bacterial infection are a fundamental properties of innate immunity. Here, we describe an effector B cell population that protects against microbial sepsis. Innate response activator (IRA) B cells are phenotypically and functionally distinct, develop and diverge from B1a B cells, depend on pattern-recognition receptors, and produce granulocyte-macrophage colony-stimulating factor. Specific deletion of IRA B cell activity impairs bacterial clearance, elicits a cytokine storm, and precipitates septic shock. These observations enrich our understanding of innate immunity, position IRA B cells as gatekeepers of bacterial infection, and identify new treatment avenues for infectious diseases.
Trends in Immunology | 2013
Mario Leonardo Squadrito; Martin Etzrodt; Michele De Palma; Mikael J. Pittet
Deregulation of microRNAs (miRNAs) can drive oncogenesis, tumor progression, and metastasis by acting cell-autonomously in cancer cells. However, solid tumors are also infiltrated by large amounts of non-neoplastic stromal cells, including macrophages, which express several active miRNAs. Tumor-associated macrophages (TAMs) enhance angiogenic, immunosuppressive, invasive, and metastatic programming of neoplastic tissue and reduce host survival. Here, we review the role of miRNAs (including miR-155, miR-146, and miR-511) in the control of macrophage production and activation, and examine whether reprogramming miRNA activity in TAMs and/or their precursors might be effective for controlling tumor progression.
Cell Stem Cell | 2014
Martin Etzrodt; Max Endele; Timm Schroeder
Understanding the molecular control of cell fates is central to stem cell research. Such insight requires quantification of molecular and cellular behavior at the single-cell level. Recent advances now permit high-throughput molecular readouts from single cells as well as continuous, noninvasive observation of cell behavior over time. Here, we review current state-of-the-art approaches used to query stem cell fate at the single-cell level, including advances in lineage tracing, time-lapse imaging, and molecular profiling. We also offer our perspective on the advantages and drawbacks of available approaches, key technical limitations, considerations for data interpretation, and future innovation.
Nature | 2016
Philipp S. Hoppe; Michael Schwarzfischer; Dirk Loeffler; Konstantinos D. Kokkaliaris; Oliver Hilsenbeck; Nadine Moritz; Max Endele; Adam Filipczyk; Adriana Gambardella; Nouraiz Ahmed; Martin Etzrodt; Daniel L. Coutu; Michael A. Rieger; Carsten Marr; Michael Strasser; Bernhard Schauberger; Ingo Burtscher; Olga Ermakova; Antje Bürger; Heiko Lickert; Claus Nerlov; Fabian J. Theis; Timm Schroeder
The mechanisms underlying haematopoietic lineage decisions remain disputed. Lineage-affiliated transcription factors with the capacity for lineage reprogramming, positive auto-regulation and mutual inhibition have been described as being expressed in uncommitted cell populations. This led to the assumption that lineage choice is cell-intrinsically initiated and determined by stochastic switches of randomly fluctuating cross-antagonistic transcription factors. However, this hypothesis was developed on the basis of RNA expression data from snapshot and/or population-averaged analyses. Alternative models of lineage choice therefore cannot be excluded. Here we use novel reporter mouse lines and live imaging for continuous single-cell long-term quantification of the transcription factors GATA1 and PU.1 (also known as SPI1). We analyse individual haematopoietic stem cells throughout differentiation into megakaryocytic–erythroid and granulocytic–monocytic lineages. The observed expression dynamics are incompatible with the assumption that stochastic switching between PU.1 and GATA1 precedes and initiates megakaryocytic–erythroid versus granulocytic–monocytic lineage decision-making. Rather, our findings suggest that these transcription factors are only executing and reinforcing lineage choice once made. These results challenge the current prevailing model of early myeloid lineage choice.
PLOS ONE | 2009
Moritz Wildgruber; Hakho Lee; Aleksey Chudnovskiy; Tae-Jong Yoon; Martin Etzrodt; Mikael J. Pittet; Matthias Nahrendorf; Kevin Croce; Peter Libby; Ralph Weissleder; Filip K. Swirski
Monocytes are circulating macrophage and dendritic cell precursors that populate healthy and diseased tissue. In humans, monocytes consist of at least two subsets whose proportions in the blood fluctuate in response to coronary artery disease, sepsis, and viral infection. Animal studies have shown that specific shifts in the monocyte subset repertoire either exacerbate or attenuate disease, suggesting a role for monocyte subsets as biomarkers and therapeutic targets. Assays are therefore needed that can selectively and rapidly enumerate monocytes and their subsets. This study shows that two major human monocyte subsets express similar levels of the receptor for macrophage colony stimulating factor (MCSFR) but differ in their phagocytic capacity. We exploit these properties and custom-engineer magnetic nanoparticles for ex vivo sensing of monocytes and their subsets. We present a two-dimensional enumerative mathematical model that simultaneously reports number and proportion of monocyte subsets in a small volume of human blood. Using a recently described diagnostic magnetic resonance (DMR) chip with 1 µl sample size and high throughput capabilities, we then show that application of the model accurately quantifies subset fluctuations that occur in patients with atherosclerosis.
Nature Biotechnology | 2016
Oliver Hilsenbeck; Michael Schwarzfischer; Stavroula Skylaki; Bernhard Schauberger; Philipp S. Hoppe; Dirk Loeffler; Konstantinos D. Kokkaliaris; Simon Hastreiter; Eleni Skylaki; Adam Filipczyk; Michael Strasser; Felix Buggenthin; Justin Feigelman; Jan Krumsiek; Adrianus J J van den Berg; Max Endele; Martin Etzrodt; Carsten Marr; Fabian J. Theis; Timm Schroeder
Software tools for single-cell tracking and quantification of cellular and molecular properties